Aldiban W, Aljamali M, Youssef L
BMC Genomics. 2025; 26(1):140.
PMID: 39948503
PMC: 11823145.
DOI: 10.1186/s12864-025-11310-9.
Zhao J, Bian J, Zhao Y, Li Y, Liu B, Hao X
Paediatr Drugs. 2023; 25(3):301-319.
PMID: 36707496
DOI: 10.1007/s40272-023-00560-3.
Zhao W, Meng H
Bioengineered. 2022; 13(3):7709-7745.
PMID: 35290166
PMC: 9278974.
DOI: 10.1080/21655979.2022.2036916.
Ustare L, Reyes K, Lasac M, Brodit Jr S, Baclig M
Int J Mol Epidemiol Genet. 2020; 11(2):31-38.
PMID: 33240461
PMC: 7677506.
Biswas M, Bendkhale S, Deshpande S, Thaker S, Kulkarni D, Bhatia S
Indian Heart J. 2019; 70 Suppl 3:S13-S19.
PMID: 30595245
PMC: 6309143.
DOI: 10.1016/j.ihj.2018.02.005.
Early post-traumatic seizures are associated with valproic acid plasma concentrations and UGT1A6/CYP2C9 genetic polymorphisms in patients with severe traumatic brain injury.
Sun Y, Yu J, Yuan Q, Wu X, Wu X, Hu J
Scand J Trauma Resusc Emerg Med. 2017; 25(1):85.
PMID: 28841884
PMC: 5574127.
DOI: 10.1186/s13049-017-0382-0.
The allele frequency of and in the Southern Khorasan population.
Emadian Razavi F, Zarban A, Hajipoor F, Naseri M
Res Pharm Sci. 2017; 12(3):211-221.
PMID: 28626479
PMC: 5465830.
DOI: 10.4103/1735-5362.207202.
Cytochrome P450 2C9 (CYP2C9) polymorphisms in Chinese Li population.
Ding Y, Yang D, Zhou L, He P, Yao J, Xie P
Int J Clin Exp Med. 2016; 8(11):21024-33.
PMID: 26885033
PMC: 4723878.
Characterization of drug-metabolizing enzymes CYP2C9, CYP2C19 polymorphisms in Tunisian, Kuwaiti and Bahraini populations.
Abdelhedi R, Bouayed N, AlFadhli S, Abid L, Rebai A, Kharrat N
J Genet. 2015; 94(4):765-70.
PMID: 26690534
DOI: 10.1007/s12041-015-0581-2.
Search for genetic determinants of sulfonylurea efficacy in type 2 diabetic patients from China.
Ren Q, Han X, Tang Y, Zhang X, Zou X, Cai X
Diabetologia. 2013; 57(4):746-53.
PMID: 24356749
DOI: 10.1007/s00125-013-3146-z.
Cytochrome P450 (CYP2C9*2,*3) & vitamin-K epoxide reductase complex (VKORC1 -1639G<A) gene polymorphisms & their effect on acenocoumarol dose in patients with mechanical heart valve replacement.
Kaur A, Khan F, Agrawal S, Kapoor A, Agarwal S, Phadke S
Indian J Med Res. 2013; 137(1):203-9.
PMID: 23481074
PMC: 3657889.
Genotype-phenotype correlation of cytochrome P450 2C9 polymorphism in Indian National Capital Region.
Varshney E, Saha N, Tandon M, Shrivastava V, Ali S
Eur J Drug Metab Pharmacokinet. 2013; 38(4):275-82.
PMID: 23446815
DOI: 10.1007/s13318-013-0124-2.
Analysis of CYP2C9*2, CYP2C9*3 and VKORC1 -1639 G>A polymorphisms in a population from South-Eastern Europe.
Buzoianu A, Trifa A, Muresanu D, Crisan S
J Cell Mol Med. 2012; 16(12):2919-24.
PMID: 22863573
PMC: 4393720.
DOI: 10.1111/j.1582-4934.2012.01606.x.
Lipid-lowering effect of fluvastatin in relation to cytochrome P450 2C9 variant alleles frequently distributed in the Czech population.
Buzkova H, Pechandova K, Danzig V, Vareka T, Perlik F, Zak A
Med Sci Monit. 2012; 18(8):CR512-517.
PMID: 22847201
PMC: 3560696.
DOI: 10.12659/msm.883272.
Frequency of CYP2C9 alleles in Koreans and their effects on losartan pharmacokinetics.
Bae J, Choi C, Kim M, Oh D, Keum S, Park J
Acta Pharmacol Sin. 2011; 32(10):1303-8.
PMID: 21841812
PMC: 4010224.
DOI: 10.1038/aps.2011.100.
Implementing genotype-guided antithrombotic therapy.
Seip R, Duconge J, Ruano G
Future Cardiol. 2010; 6(3):409-24.
PMID: 20462345
PMC: 2903229.
DOI: 10.2217/fca.10.6.
Influence of CYP2C9 and CYP2C19 genetic polymorphisms on phenytoin-induced neurological toxicity in Indian epileptic patients.
Kesavan R, Narayan S, Adithan C
Eur J Clin Pharmacol. 2010; 66(7):689-96.
PMID: 20390258
DOI: 10.1007/s00228-010-0817-2.
Cytochrome P450 2C9-CYP2C9.
Van Booven D, Marsh S, Mcleod H, Whirl Carrillo M, Sangkuhl K, Klein T
Pharmacogenet Genomics. 2010; 20(4):277-81.
PMID: 20150829
PMC: 3201766.
DOI: 10.1097/FPC.0b013e3283349e84.
Effects of CYP2C19 and CYP2C9 genotypes on pharmacokinetic variability of valproic acid in Chinese epileptic patients: nonlinear mixed-effect modeling.
Jiang D, Bai X, Zhang Q, Lu W, Wang Y, Li L
Eur J Clin Pharmacol. 2009; 65(12):1187-93.
PMID: 19756559
DOI: 10.1007/s00228-009-0712-x.
Evidence for a pharmacogenetic adapted dose of oral anticoagulant in routine medical practice.
Becquemont L
Eur J Clin Pharmacol. 2008; 64(10):953-60.
PMID: 18758764
DOI: 10.1007/s00228-008-0542-2.